MammaPrint® + BluePrint®
Every woman deserves a unique treatment strategy
MammaPrint® + BluePrint® together help address the complexity of early breast cancer
Are you receiving the complete information to make timely decisions about the optimal treatment?
1 in 8 women will be diagnosed with breast cancer in her lifetime.
Treatment plan information is crucial to improving patient outcomes and management.
More than 33,000 new cases of breast cancer in Spain in 2019
What do we offer you as valuable information for decision making?
MammaPrint®
Relapse risk test
MammaPrint®, 70-gene breast cancer relapse test, is the first FDA approved and CE marked test, supported by peer-reviewed data from prospective studies included in major treatment guidelines.
- Study genes involved in each study of the metastatic cascade
- Results are independent and complementary to standard IHC/FISH tests
-
MammaPrint® allows to predict the risk of relapse of the disease
-
Helps personalize treatment to avoid treatments that are unnecessary
BluePrint®
Functional molecular subtyping
BluePrint®, the 80-gene molecular substaging test, goes beyond the surface cells, evaluating the underlying biology that drives tumor growth.
-
BluePrint® identifies the underlying biology driving tumor growth and enables more accurate molecular substaging to be identified
-
Approximately 1 in 5 pathologically RH+ women are reclassified to Basal Type-High Risk tumors
Patient cases
How do we minimize under and over treatment in the pre-operative setting?
Case to study
Patient presents a large tumor
Clinical features
- 61-year-old patient
- Invasive ductal tumor of 4,5cm
- ER+ 90%, 80% by IHC
HER2 negative by IHC and FISH - Clinically negative node
- Grade 2
Genomic results
- BluePrint Luminal A-Type
- MammaPrint Low Risk
How do we minimize under and over treatment in the pre-operative setting?
Case to study
Patient presents a Small RH+ Tumor
The patient is going on vacation for 2 months and would like to postpone her cancer treatment if possible
Clinical features
- 31-year-old patient
- 1,8cm tumor
- ER+ 90%, PR- by IHC
- HER2 negative by IHC and FISH
- Clinically negative node
- Grade 2
Genomic results
- BluePrint Basal-Type
- MammaPrint High Risk
How do we minimize under and over treatment in the pre-operative setting?
Case to study
Patient presents an RH+ Tumor
Patient has side effects and wants to discontinue endocrine therapy
Clinical features
- 57-year-old patient
- 2,1cm tumor
- ER+ 100%, RP+ 85% by IHC
- HER2 negative by IHC and FISH
- Clinically negative node
- Grade 1
Genomic results
- BluePrint Luminal A-Type
- MammaPrint Ultralow Risk
How do we minimize under and over treatment in the pre-operative setting?
Case to study
LN+ breast cancer patient
Clinical features
- 55-year-old patient
- 3cm tumor
- ER+ 90%, RP+ 90% by IHC
- HER2 negative by IHC and FISH
- Positive node
- Grade 2
Genomic results
- BluePrint Luminal A-Type
- MammaPrint Low Risk
How to request it?
